Wild Bioscience has raised $60 million in a Series A round led by the EIT, alongside Oxford Science Enterprises (OSE), Braavos Capital, and the Uni Oxford.
01 October 2025
01 October 2025
Total investments received (USD): 60M
Round value (USD): 60M
Company: Wild Bioscience
Related deals
Immutrin in a £65M series A led by Frazier Life Sciences, joined by SR One, Qiming Venture Partners, Cambridge Enterprise Ventures and F-Prime
Investments
07 March 2026
Isembard raised $50m Series A funding led by USV, joined by Tamarack Global, IQ Capital, Notion Capital, CIV and angel investors.
Investments
01 March 2026
Calogena in a €52 million private equity investment (capital increase) from Gorgé SA, SNEF Group, and Caisse des Dépôts
Investments
01 March 2026
R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
Investments
01 March 2026
Chemify in a $50 million equity deal series B Extension backed by Zeon ventures from Japan
Investments
14 February 2026
Belgium
Netherlands
Austria
Germany
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
Ireland
Italy
Portugal
Spain